Boston Scientific (BSX) Gains from Investment Securities (2020 - 2026)

Boston Scientific has reported Gains from Investment Securities for 7 years, with the latest figure at -$16.0 million in Q2 2026.

• Gains from Investment Securities for Q2 2026 came in at -$16.0 million, down 220.0% year-over-year; the trailing twelve-month figure through Jun 2026 was -$28.0 million (down 16.67% YoY), and the FY2025 annual result was $18.0 million, up 460.0% from the prior year.
• Gains from Investment Securities improved to -$16.0 million in Q2 2026, from -$30.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $36.0 million in Q2 2022 and troughed at -$33.0 million in Q4 2022.
• A 5-year average of $3.3 million and a median of $9.0 million in 2025 frame the typical range for Gains from Investment Securities.
• The widest annual swing landed in 2025, when Gains from Investment Securities surged 800.0%; it then sank 700.0% in 2026.
• A 5-year view of Gains from Investment Securities shows it stood at -$33.0 million in 2022, then soared by 145.45% to $15.0 million in 2023, then sank by 106.67% to -$1.0 million in 2024, then surged by 800.0% to $7.0 million in 2025, then sank by 328.57% to -$16.0 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were -$16.0 million in Q2 2026, -$30.0 million in Q1 2026, and $7.0 million in Q4 2025.